147 related articles for article (PubMed ID: 21209853)
1. The cooperation between hMena overexpression and HER2 signalling in breast cancer.
Di Modugno F; Mottolese M; DeMonte L; Trono P; Balsamo M; Conidi A; Melucci E; Terrenato I; Belleudi F; Torrisi MR; Alessio M; Santoni A; Nisticò P
PLoS One; 2010 Dec; 5(12):e15852. PubMed ID: 21209853
[TBL] [Abstract][Full Text] [Related]
2. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
4. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
[TBL] [Abstract][Full Text] [Related]
5. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Pino MS; Balsamo M; Di Modugno F; Mottolese M; Alessio M; Melucci E; Milella M; McConkey DJ; Philippar U; Gertler FB; Natali PG; Nisticò P
Clin Cancer Res; 2008 Aug; 14(15):4943-50. PubMed ID: 18676769
[TBL] [Abstract][Full Text] [Related]
6. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
7. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
[TBL] [Abstract][Full Text] [Related]
9. hMENA(11a), a hMENA isoform sending survival signals.
Trono P; Di Modugno F; Nisticò P
Mol Cell Oncol; 2016 Mar; 3(2):e1083648. PubMed ID: 27308605
[TBL] [Abstract][Full Text] [Related]
10. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
11. hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Di Modugno F; Spada S; Palermo B; Visca P; Iapicca P; Di Carlo A; Antoniani B; Sperduti I; Di Benedetto A; Terrenato I; Mottolese M; Gandolfi F; Facciolo F; Chen EI; Schwartz MA; Santoni A; Bissell MJ; Nisticò P
Oncogene; 2018 Oct; 37(42):5605-5617. PubMed ID: 29907768
[TBL] [Abstract][Full Text] [Related]
12. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
13. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.
Melchionna R; Iapicca P; Di Modugno F; Trono P; Sperduti I; Fassan M; Cataldo I; Rusev BC; Lawlor RT; Diodoro MG; Milella M; Grazi GL; Bissell MJ; Scarpa A; Nisticò P
Oncoimmunology; 2016; 5(12):e1221556. PubMed ID: 28123868
[TBL] [Abstract][Full Text] [Related]
14. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
16. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression.
Toyoda A; Kawana H; Azuhata K; Yu J; Omata A; Kishi H; Higashi M; Harigaya K
Int J Oncol; 2009 Jan; 34(1):53-60. PubMed ID: 19082477
[TBL] [Abstract][Full Text] [Related]
18. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
19. GLMEEMSAL epitope common in different isoforms of hMena elicits in vitro activation of cytotoxic T cells and stimulates specific antitumor immunity in BALB/c mice.
Don-López CA; Monroy-García A; Weiss-Steider B; Rocha-Zavaleta L; Hernández-Montes J; García-Rocha R; Mora-García ML
Int Immunopharmacol; 2018 Mar; 56():291-300. PubMed ID: 29414664
[TBL] [Abstract][Full Text] [Related]
20. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
